Vertex Braces For HCV Combo Paradigm With ViroChem Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeover gives Vertex two clinical-stage polymerase inhibitors, and recalls Gilead’s key Triangle grab.
You may also be interested in...
Drop Two, Add One: Vertex Adjusts Adaptive Trial Seeking An All-Oral HCV Regimen
Vertex Pharmaceuticals, Inc., is adjusting an ongoing trial that tests its potential first-in-class protease inhibitor telaprevir in combinations it hopes will lead to an all-oral cocktail that is effective against genotype 1 hepatitis C, the firm announced Dec. 21.
Drop Two, Add One: Vertex Adjusts Adaptive Trial Seeking An All-Oral HCV Regimen
Vertex Pharmaceuticals, Inc., is adjusting an ongoing trial that tests its potential first-in-class protease inhibitor telaprevir in combinations it hopes will lead to an all-oral cocktail that is effective against genotype 1 hepatitis C, the firm announced Dec. 21.
Drop Two, Add One: Vertex Adjusts Adaptive Trial Seeking An All-Oral HCV Regimen
The ongoing Phase II study trying combinations backboned by telaprevir and experimental polymerase inhibitor VX-222 continues with two quad-treatment arms and a plan to drop interferon again in the first quarter.